Exercise and the Menstrual Cycle in Type 1 Diabetes
Key facts
- Where
- Edmonton, CanadaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 50 years old?
Source: NCT05188014, who can take part
Where in Canada
- Alberta Diabetes InstituteEdmonton, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Alberta
- Trial code
- NCT05188014
- Record updated
- 20 July 2026
- Original description
Female participants with type 1 diabetes using oral contraceptives will be asked to wear a continuous glucose monitor for at least three days on two separate occasions (once during the last week of active pills and once during the no pill/placebo pill phase of the menstrual cycle). An exercise session (45 minutes of aerobic exercise at 60% VO2peak on a cycle ergometer) will take place at 5 pm on the second day of glucose monitoring.Read full original descriptionShow less
Effects of the Menstrual Cycle on Blood Glucose Changes During Exercise in Women With Type 1 Diabetes Using Oral Contraceptives
Female participants with type 1 diabetes using oral contraceptives will be asked to wear a continuous glucose monitor for at least three days on two separate occasions (once during the last week of active pills and once during the no pill/placebo pill phase of the menstrual cycle). An exercise session (45 minutes of aerobic exercise at 60% VO2peak on a cycle ergometer) will take place at 5 pm on the second day of glucose monitoring.
Inclusion: type 1 diabetes diagnosed for at least 1 year; regular menses; using monophasic oral contraceptives; residing in Edmonton, Alberta and able to visit the lab at the University of Alberta.
Exclusion: history of cardiovascular disease; any musculoskeletal condition that would contraindicate exercise (e.g. sprain, strain, joint injury, etc.); HbA1c > 9.9%; use of medications (other than insulin) that would affect blood glucose levels; frequent and unpredictable hypoglycemia; change in insulin management strategy within two months of the study; use of an automated insulin delivery system; blood pressure > 140/95; severe peripheral neuropathy; active proliferative retinopathy.